CDM Projects

This study is a replication of the drug utilization study conducted by INESSS using data from Quebec to gather data from 6 additional provinces. The objectives are to identify incident and prevalent cases of major neurocognitive disorder among older adults and describe their characteristics and a set of indicators of the use of potentially inappropriate medications. The results from the Quebec study will be included into the overall findings.

This study will replicate a FDA Sentinel study using the CNODES' adaptation of the Sentinel Common Data Model with Canadian data to determine whether there is an increased risk of intentional self-harm among adult patients with diabetes who are newly treated with GLP-1 receptor agonists compared to those who are newly treated with SGLT-2 inhibitors or DPP-4 inhibitors.

Further focused studies are necessary to establish the presence of meaningful safety signals of Ozempic. Our study provides important lessons for the future use of Canadian data in TreeScan-based analyses.

The current available real-world evidence on the potential association between GLP-1 receptor agonists and the risk of suicidality and self-harm is limited, as the studies had contradictory findings and important methodological limitations.

Outpatient nirmatrelvir-ritonavir use varied across provinces. Remdesivir use, in the provinces for which utilization data was available, was low overall. Utilization of both therapies gradually decreased from October 2022, suggesting declining demand in this patient setting.

It is not possible to draw conclusions about associations between the use of tofacitinib in ulcerative colitis and safety events due to the limited number of events observed. These findings suggest that detailed safety studies of tofacitinib in ulcerative colitis are currently not feasible in our data holdings.